Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer-Reference-Cited by-同舟云学术

Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer

Published:2022-09 Issue: Volume:153 Page:113393
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Guchelaar Niels A.D.,van Eerden Ruben A.G.,Groenland Stefanie L.,Doorn Leni van,Desar Ingrid M.E.,Eskens Ferry A.L.M.,Steeghs Neeltje,van Erp Nielka P.,Huitema Alwin D.R.,Mathijssen Ron H.J.,Koolen Stijn L.W.

Funder

Novartis Pharmaceuticals Corporation

Merck

Pfizer BV

Ipsen Pharma SAS

Novartis

Pfizer

Roche

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference37 articles.

1. Sorafenib

2. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N. Engl. J. Med.,2007

3. Sorafenib in advanced hepatocellular carcinoma;Llovet;N. Engl. J. Med.,2008

4. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial;Brose;Lancet,2014

5. Sorafenib for advanced and refractory desmoid tumors;Gounder;N. Engl. J. Med.,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study;British Journal of Cancer;2024-07-06

2. Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails;Clinical Pharmacology & Therapeutics;2024-07

3. Practicality of STAT3 Gene Polymorphisms and Sorafenib Trough Concentration as Biomarkers for Sorafenib-Induced Hand-Foot Skin Reaction in Hepatocellular Carcinoma;Journal of Clinical Pharmacy and Therapeutics;2023-08-19

4. Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology;Clinical Pharmacokinetics;2023-08-16

5. Sorafenib;Reactions Weekly;2022-10-29